Cagrilintide 10mg

Cagrilintide is a novel long-acting amylin analog and dual amylin and calcitonin receptor agonist (DACRA), designed based on the structure of amylin. It regulates metabolic parameters such as body weight and blood glucose by activating both amylin and calcitonin receptors. In preclinical and clinical studies, Cagrilintide has demonstrated significant weight-loss effects and effective glycemic control. With an extended half-life of approximately 7-8 days, it allows for less frequent dosing and improved patient compliance. This advancement addresses the limitation of the shorter half-life associated with native amylin, offering a promising new treatment option for obesity and type 2 diabetes, and bringing new hope for the management of metabolic diseases.